Donafenib and sintilimab combined with hepatic arterial infusion chemotherapy for unresectable hepatocellular carcinoma: a prospective, single-arm phase II trial (DoHAICs study)
Wei Gao(Tianjin Medical University Cancer Institute and Hospital), Wei‐Yang Lu(Western University), Wei Zhang(China Pharmaceutical University), Zhao Xiao-hui(Tianjin Medical University Cancer Institute and Hospital), Chen Liu(Novartis (Switzerland)), Qiang Li(Capital Medical University), Dongyang Li(National Institute of Advanced Industrial Science and Technology), Lu Yang(Suizhou Central Hospital), Xiaomeng Liu(Tianjin Medical University Cancer Institute and Hospital), Junbo Cao(Tianjin Medical University Cancer Institute and Hospital), Xu Bao(Tianjin Medical University Cancer Institute and Hospital), Guangtao Li(Tianjin Medical University Cancer Institute and Hospital), Weihao Zhang(Tianjin Medical University Cancer Institute and Hospital), Wenge Xing(Tianjin Medical University Cancer Institute and Hospital), Xiaolin Zhu(The First Affiliated Hospital, Sun Yat-sen University), Zhao-Long Pan(Tianjin Medical University Cancer Institute and Hospital), Tian-Qiang Song(Tianjin Medical University Cancer Institute and Hospital)
Cited by 9
Related Papers
Genomic analysis identifies association of <i>Fusobacterium</i> with colorectal carcinoma
|Genome Research|2011|2k
Adjunctive Glucocorticoid Therapy in Patients with Septic Shock
|New England Journal of Medicine|2018|992
Follow-up of Blood-Pressure Lowering and Glucose Control in Type 2 Diabetes
|New England Journal of Medicine|2014|624
Low-Dose versus Standard-Dose Intravenous Alteplase in Acute Ischemic Stroke
|New England Journal of Medicine|2016|437